(Q35026523)

5 August 2017

title

Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs (English)

1 reference

5 August 2017

Mark M

1

1 reference

5 August 2017

Grell W

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 August 1997

1 reference

British Journal of Pharmacology

5 August 2017

published in

1 reference

5 August 2017

volume

121

1 reference

5 August 2017

issue

8

1 reference

5 August 2017

page(s)

1597-1604

1 reference

Highly potent and stereoselective effects of the benzoic acid derivative AZ-DF 265 on pancreatic beta-cells

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

Clinical profile of glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

7 January 2021

Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

7 January 2021

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

7 January 2021

Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

7 January 2021

Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

7 January 2021

Blood glucose lowering sulfonamides with asymmetric carbon atoms. 3. Related N-substituted carbamoylbenzoic acids

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

7 January 2021

Evidence for more than one binding site for sulfonylureas in insulin-secreting cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

7 January 2021

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701307

7 January 2021

Identifiers

DOI

10.1038/SJ.BJP.0701307

1 reference

5 August 2017

1 reference

5 August 2017

1 reference